Correlations between monocyte-to-lymphocyte ratio with coronary heart disease and the extent of coronary atherosclerosis

doi:10.3969/j.issn.1673-8640.2024.05.013

Abstract

Abstract:

Objective To investigate the correlation of monocyte-to-lymphocyte ratio（MLR） with coronary heart disease（CHD） and the extent of coronary atherosclerosis. Methods A total of 200 CHD patients with positive coronary angiography results（major vessel diameter ≥50%） in North Branch of Ruijin Hospital of Shanghai Jiao Tong University School of Medicine from June to December 2022 were enrolled as CHD group，and 131 patients with negative coronary angiography results during the same period were enrolled as control group. The difference of MLR，neutrophil-to-lymphocyte ratio（NLR） and platelet-to-lymphocyte ratio（PLR） was evaluated between CHD and control groups. The correlations between MLR and creatine kinase（CK），lactate dehydrogenase（LDH） and Gensini scores were evaluated by Pearson or Spearman correlation analysis. Logistic regression analysis was used to evaluate the influencing factors of CHD. Receiver operating characteristic（ROC） curve was used to evaluate the efficacy of MLR in diagnosing CHD. Results MLR，NLR and PLR in CHD group were higher than those in control group（P<0.001）. There was no statistical significance in MLR between CHD group and control group after therapy（P>0.05）. MLR was positively correlated with CK，LDH and Gensini scores in CHD patients（r values were 0.150 0，0.290 0 and 0.545 1，P<0.05）. CK，MLR，NLR and PLR were all influencing factors of CHD. After adjusting for confounding factors，the risk of CHD was 1.6 times higher when MLR>0.25 than when MLR≤0.17 [odds ratio（OR）=1.609，95% confidence interval（CI） 1.213-2.133]. The area under curve of MLR for diagnosing CHD was 0.674 3，the sensitivity was 62.00%，and the specificity was 62.60%. Conclusions MLR is related with CHD and the extent of coronary atherosclerosis，and it may be an independent predictor of the extent of coronary atherosclerosis in CHD patients，which can help clinical judgement whether to proceed with further invasive treatment.

Key words: Monocyte-to-lymphocyte ratio, Coronary heart disease, Coronary atherosclerosis, Gensini score

CLC Number:

R446.11

LIU Lin, WANG Tiankai, QIN Kangchunfeng, DING Ning. Correlations between monocyte-to-lymphocyte ratio with coronary heart disease and the extent of coronary atherosclerosis[J]. Laboratory Medicine, 2024, 39(5): 485-490.

Figures/Tables 9

References 30

[1]	CHAN Y H, RAMJI D P. A perspective on targeting inflammation and cytokine actions in atherosclerosis[J]. Future Med Chem, 2020, 12(7):613-626.
[2]	SONG P, FANG Z, WANG H, et al. Global and regional prevalence,burden,and risk factors for carotidatherosclerosis:a systematic review,meta-analysis,and modelling study[J]. Lancet Glob Health, 2020, 8(5):e721-e729.
[3]	TSAO C W, ADAY A W, ALMARZOOQ Z I, et al. Heart disease and stroke statistics-2022 update:a report from the American Heart Association[J]. Circulation, 2022, 145(8):e153-e639.
[4]	徐卫峰, 关海旺, 潘靖南, 等. 不同年龄阶段淋巴细胞/单核细胞比值与稳定性冠心病Syntax积分的相关性研究[J]. 临床心血管病杂志, 2019, 35(7):609-615.
[5]	秦雪婷, 陈润都, 张仲柏, 等. 女性急性心肌梗死患者单核细胞与淋巴细胞比值和短期内发生主要心血管不良事件相关性研究[J]. 中国循证心血管医学杂志, 2019, 11(12):1520-1523.
[6]	LIN P, JI H H, LI Y J, et al. Macrophage plasticity and atherosclerosis therapy[J]. Front Mol Biosci, 2021, 8:679797.
[7]	ORTEGA-PAZ L, CAPODANNO D, ANGIOLILLO D J. Canakinumab for secondary prevention of coronary artery disease[J]. Future Cardiol, 2021, 17(3):427-442.
[8]	SHAH P K. Inflammation,infection and atherosclerosis[J]. Trends Cardiovasc Med, 2019, 29(8):468-472.
[9]	TUÑÓN J, BÄCK M, BADIMÓN L, et al. Interplay between hypercholesterolaemia and inflammation in atherosclerosis:translating experimental targets into clinical practice[J]. Eur J Prev Cardiol, 2018, 25(9):948-955.
[10]	ADAMSTEIN N H, MACFADYEN J G, ROSE L M, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events:analyses from five contemporary randomized trials[J]. Eur Heart J, 2021, 42(9):896-903.
[11]	KLISIC A, RADOMAN VUJAI I, VUKOVI L J, et al. Total leukocyte count,leukocyte subsets and their indexes in relation tocardiovascular risk in adolescent population[J]. Eur Rev Med Pharmacol Sci, 2021, 25(7):3038-3044.
[12]	MANOOCHEHRI H, GHEITASI R, POURJAFAR M, et al. Investigating the relationship between the severity of coronary artery diseaseand inflammatory factors of MHR,PHR,NHR,and IL-25[J]. Med J Islam Repub Iran, 2021, 35:85.
[13]	URBANOWICZ T, OLASISKA-WINIEWSKA A, MICHALAK M, et al. The prognostic significance of neutrophil to lymphocyte ratio(NLR),monocyte to lymphocyte ratio(MLR)and platelet to lymphocyte ratio(PLR)on long-term survival in off-pump coronary artery bypass grafting(OPCAB)procedures[J]. Biology(Basel), 2021, 11(1):34.
[14]	LOMBARDI G, PAGANELLI R, ABATE M, et al. Leukocyte-derived ratios are associated with late-life any type dementia:across-sectional analysis of the mugello study[J]. Geroscience, 2021, 43(6):2785-2793.
[15]	ZHANG N, TSE G, LIU T. Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis[J]. Eur Heart J, 2021, 42(22):2215. DOI PMID
[16]	ZHANG T Y, ZHAO Q, LIU Z S, et al. Relationship between monocyte/lymphocyte ratio and non-culprit plaque vulnerability in patients with acute coronary syndrome:an optical coherence tomography study[J]. Medicine(Baltimore), 2020, 99(41):e21562.
[17]	中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9):680-694.
[18]	王春, 秦少博. 炎症与血管内皮损伤研究进展[J]. 心血管病学进展, 2015, 36(1):89-92.
[19]	MARCUZZI A, MELLONI E, ZAULI G, et al. Autoinflammatory diseases and cytokine storms-imbalances of innate and adaptative immunity[J]. Int J Mol Sci, 2021, 22(20):11241.
[20]	WOLF D, LEY K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019, 124(2):315-327. DOI PMID
[21]	ZEYNALOVA S, BUCKSCH K, SCHOLZ M, et al. Monocyte subtype counts are associated with 10-year cardiovascular disease riskas determined by the Framingham risk score among subjects of the LIFE-adult study[J]. PLoS One, 2021, 16(3):e0247480.
[22]	SHAH AD, DENAXAS S, NICHOLAS O, et al. Neutrophil counts and initial presentation of 12 cardiovascular diseases:aCALIBER cohort study[J]. J Am Coll Cardiol, 2017, 69(9):1160-1169.
[23]	KOUNIS N G, KONIARI I, PLOTAS P, et al. Inflammation,thrombosis,and platelet-to-lymphocyte ratio in acute coronarysyndromes[J]. Angiology, 2021, 72(1):6-8.
[24]	CHO Y, BALDÁN A. Quest for new biomarkers in atherosclerosis[J]. Mo Med, 2013, 110(4):325-330. PMID
[25]	BLAIR P, REX S, VITSEVA O, et al. Stimulation of toll-like receptor 2 in human platelets induces athrombo inflammatory response through activation of phosphoinositide 3-kinase[J]. Circ Res, 2009, 104(3):346-354.
[26]	BOEKHOLDT S M, PETERS R J, DAY N E, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke:the EPIC-Norfolk Prospective Population study[J]. Am J Med, 2004, 117(6):390-397.
[27]	YU C, CHEN M, CHEN Z, et al. Predictive and prognostic value of admission neutrophil-to-lymphocyte ratio in patients with CHD[J]. Herz, 2016, 41(7):605-613. PMID
[28]	LI X, LI J, WU G. Relationship of neutrophil-to-lymphocyte ratio with carotid plaque vulnerability and occurrence of vulnerable carotid plaque in patients with acute ischemic stroke[J]. Biomed Res Int, 2021, 2021:6894623.
[29]	KOSE N, AKIN F, YILDIRIM T, et al. The association between the lymphocyte-to-monocyte ratio and coronary artery disease severity in patients with stable coronary artery disease[J]. Eur Rev Med Pharmacol Sci, 2019, 23(6):2570-2575.
[30]	苏广胜. 青年冠心病患者中性粒细胞与淋巴细胞比值与冠状动脉病变严重程度的关系[J]. 中国循证心血管医学杂志, 2018, 10(11):1379-1384.

狭窄程度	积分/分	病变部位	病变系数
≤25%	1	左主干	5.0
26%~50%	2	前降支或回旋支近段	2.5
51%~75%	4	前降支中段	1.5
76%~90%	8	回旋支中远段和前降支远段	1.0
91%~99%	16	右冠状动脉	1.0
100%	32	其他分支	0.5

狭窄程度	积分/分	病变部位	病变系数
≤25%	1	左主干	5.0
26%~50%	2	前降支或回旋支近段	2.5
51%~75%	4	前降支中段	1.5
76%~90%	8	回旋支中远段和前降支远段	1.0
91%~99%	16	右冠状动脉	1.0
100%	32	其他分支	0.5

组别	例数	性别		年龄/岁	MLR	NLR	PLR
组别	例数	男/[例（%）]	女/[例（%）]	年龄/岁	MLR	NLR	PLR
对照组	131	92（70.23）	39（29.77）	60.32±8.16	0.20 （0.17，0.25）	2.05 （1.55，2.68）	100.98 （80.20，129.87）
CHD组	200	144（72.00）	56（28.00）	61.87±10.95	0.26 （0.19，0.35）	2.65 （1.83，3.82）	126.47 （102.09，158.90）
统计值		0.12		1.38	4.92	4.67	3.26
P值		0.728 0		0.168 0	<0.000 1	<0.000 1	0.001 2

组别	例数	性别		年龄/岁	MLR	NLR	PLR
组别	例数	男/[例（%）]	女/[例（%）]	年龄/岁	MLR	NLR	PLR
对照组	131	92（70.23）	39（29.77）	60.32±8.16	0.20 （0.17，0.25）	2.05 （1.55，2.68）	100.98 （80.20，129.87）
CHD组	200	144（72.00）	56（28.00）	61.87±10.95	0.26 （0.19，0.35）	2.65 （1.83，3.82）	126.47 （102.09，158.90）
统计值		0.12		1.38	4.92	4.67	3.26
P值		0.728 0		0.168 0	<0.000 1	<0.000 1	0.001 2

项目	OR值（95%CI）	P值
TG	1.275（1.055 ~ 1.542）	0.012
TC	0.866（0.721 ~ 1.039）	0.121
HDL-C	0.845（0.620 ~ 1.151）	0.286
LDL-C	0.794（0.614 ~ 1.027）	0.078
LDH	1.005（1.002 ~ 1.008）	<0.001
CK	1.003（1.001 ~ 1.005）	0.001
MLR	6.052（4.661 ~ 7.857）	<0.001
NLR	1.565（1.293 ~ 1.893）	<0.001
PLR	1.009（1.004 ~ 1.014）	0.001